Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EGb 761

Drug Profile

EGb 761

Alternative Names: GBE 761; Gingogink; Ginkgo biloba special extract - Dr Wilmar Schwabe Group/Ipsen; Tanakan; Tebonin; Tebonin® konzent; Tramisal

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dr. Willmar Schwabe Pharmaceuticals
  • Developer Dr. Willmar Schwabe Pharmaceuticals; Ipsen
  • Class Antidementias; Antiplatelets; Herbal medicines; Phytotherapies
  • Mechanism of Action Antioxidants; Nitric oxide synthase type II inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Alzheimer's disease; Cognition disorders; Ear disorders; Eye disorders; Neurological disorders; Vascular disorders
  • No development reported Friedreich's ataxia; Tinnitus; Vertigo
  • Discontinued Pancreatic cancer

Most Recent Events

  • 08 Apr 2021 No recent reports of Phase-II development identified for Vertigo in Poland (PO)
  • 08 Apr 2021 No recent reports of Phase-II development identified for Tinnitus in Poland (PO)
  • 08 Apr 2021 No recent reports of Phase-III development identified for Tinnitus in Czech Republic (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top